key articles
Combination therapy more effective for enlarged prostate
Thursday, 4 March 2010- Like any successful team effort, the best qualities of two drugs commonly prescribed for enlarged prostate yielded better results than either of the medicines alone, according to a new study from UT...
Edited by: ES
CombAT study shows superiority of combined treatment over monotherapy
Tuesday, 29 September 2009- Combination therapy with dutasteride and tamsulosin provides significantly greater benefit than either monotherapy for various patient-reported outcomes in men with moderate-to-severe lower urinary...
Edited by: ES
Single Botox injection reduces BPH symptoms for 18 months
Tuesday, 18 August 2009- A single treatment of Botulinum Toxin Type A reduces prostate volume and associated symptoms for 18 months, according to a new study by an Italian group. After this period, the gland's volume and PSA...
Edited by: ES
BPH treatment trials among Asian men using dutasteride and tamsulosin
Tuesday, 2 June 2009- According to a recent study conducted by Korean researchers, although ethnicity-based differences in prostate size and physiology have been reported, results of benign prostatic hyperplasia (BPH) treatment...
Edited by: JV
Prostate drug tamsulosin boosts risk of cataract surgery complications
Friday, 22 May 2009- Elderly men who take tamsulosin (Flomax) for benign prostatic hyperplasia within two weeks of cataract surgery have a higher risk of serious postoperative complications, according to a case-control study...
Edited by: JV
Sexuality and the management of BPH with alfuzosin
Monday, 29 December 2008- The sexuality and the management of benign prostatic hyperplasia (BPH) with alfuzosin (SAMBA) trial evaluated the effect of alfuzosin on sexual function in men treated for BPH using two sexual function...
Edited by: JV
Vaporesection for benign prostatic hyperplasia by a 2-microm continuous-wave laser
Tuesday, 21 October 2008 - Fu et al. (2008) explored the safety and clinical efficacy of continuous-wave laser vaporesection for the treatment of obstructive benign prostatic hyperplasia (BPH).
The authors treated 72 consecutive...
Authors: Fu et al.
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A dose finding study
Friday, 3 October 2008 - Phosphodiesterase type 5 inhibitors are widely used to treat erectile dysfunction. Preliminary data have suggested phosphodiesterase type 5 inhibitor efficacy in men with lower urinary tract symptoms...
Authors: Roehrborn et al.
Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer
Friday, 26 September 2008 - Dutasteride exerts its beneficial effects on the prostate through suppression of intraprostatic dihydrotestosterone (DHT). In an analysis Rittmaster et al. (2008) assessed the effects of the approved...
Authors: Rittmaster et al.
Epidemiology of benign prostatic hyperplasia and comorbidities in racial and ethnic minority populations
Monday, 8 September 2008 - In a review, Hoke and McWilliams (2008) addressed benign prostatic hyperplasia epidemiological aspects in racial and ethnic minorities. In the United States, research into the etiology of BPH and the...
Authors: Hoke & McWilliams
